Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic

Sara E. Cosgrove, Gloria A. Vigliani, Marilyn Campion, Vance G. Fowler, Elias Abrutyn, G. Ralph Corey, Donald P. Levine, Mark Edmund Rupp, Henry F. Chambers, Adolf W. Karchmer, Helen W. Boucher

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Background. The safety of adding initial low-dose gentamicin to antistaphylococcal penicillins or vancomycin for treatment of suspected Staphylococcus aureus native valve endocarditis is unknown. This study evaluated the association between this practice and nephrotoxicity. Methods. We performed a prospective cohort study of safety data from a randomized, controlled trial of therapy for S. aureus bacteremia and native valve infective endocarditis involving 236 patients from 44 hospitals in 4 countries. Patients either received standard therapy( antistaphylococcal penicillin or vancomycin) plus initial low-dose gentamicin( n = 116) or received daptomycin monotherapy( n = 120). We measured renal adverse events and clinically significant decreased creatinine clearance in patients( 1) in the original randomized study arms and( 2) who received any initial low-dose gentamicin either, as a study medication or ≥S2 days before enrollment. Results. Renal adverse events occurred in 8( 7%) of 120 daptomycin recipients, 10( 19%) of 53 vancomycin recipients, and 11( 17%) of 63 antistaphylococcal penicillin recipients. Decreased creatinine clearance occurred in 9( 8%) of 113 of evaluable daptomycin recipients, 10( 22%) of 46 vancomycin recipients, and 16( 25%) of 63 antistaphylococcal penicillin recipients. An additional 21 patients received initial low-dose gentamicin >S2 days before study enrollment. A total of 22% of patients who received initial low-dose gentamicin versus 8% of patients who did not receive initial low-dose gentamicin experienced decreased creatinine clearance( P =.005). Independent predictors of a clinically significant decrease in creatinine clearance were age 5≥65 years and receipt of any initial low-dose gentamicin. Conclusions. Initial low-dose gentamicin as part of therapy for S. aureus bacteremia and native valve infective endocarditis is nephrotoxic and should not be used routinely, given the minimal existing data supporting its benefit.

Original languageEnglish (US)
Pages (from-to)713-721
Number of pages9
JournalClinical Infectious Diseases
Volume48
Issue number6
DOIs
StatePublished - Mar 15 2009

Fingerprint

Bacteremia
Endocarditis
Gentamicins
Vancomycin
Daptomycin
Penicillins
Creatinine
Staphylococcus aureus
Kidney
Safety
Therapeutics
Cohort Studies
Randomized Controlled Trials
Prospective Studies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Cosgrove, S. E., Vigliani, G. A., Campion, M., Fowler, V. G., Abrutyn, E., Ralph Corey, G., ... Boucher, H. W. (2009). Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic. Clinical Infectious Diseases, 48(6), 713-721. https://doi.org/10.1086/597031

Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic. / Cosgrove, Sara E.; Vigliani, Gloria A.; Campion, Marilyn; Fowler, Vance G.; Abrutyn, Elias; Ralph Corey, G.; Levine, Donald P.; Rupp, Mark Edmund; Chambers, Henry F.; Karchmer, Adolf W.; Boucher, Helen W.

In: Clinical Infectious Diseases, Vol. 48, No. 6, 15.03.2009, p. 713-721.

Research output: Contribution to journalArticle

Cosgrove, SE, Vigliani, GA, Campion, M, Fowler, VG, Abrutyn, E, Ralph Corey, G, Levine, DP, Rupp, ME, Chambers, HF, Karchmer, AW & Boucher, HW 2009, 'Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic', Clinical Infectious Diseases, vol. 48, no. 6, pp. 713-721. https://doi.org/10.1086/597031
Cosgrove SE, Vigliani GA, Campion M, Fowler VG, Abrutyn E, Ralph Corey G et al. Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic. Clinical Infectious Diseases. 2009 Mar 15;48(6):713-721. https://doi.org/10.1086/597031
Cosgrove, Sara E. ; Vigliani, Gloria A. ; Campion, Marilyn ; Fowler, Vance G. ; Abrutyn, Elias ; Ralph Corey, G. ; Levine, Donald P. ; Rupp, Mark Edmund ; Chambers, Henry F. ; Karchmer, Adolf W. ; Boucher, Helen W. / Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic. In: Clinical Infectious Diseases. 2009 ; Vol. 48, No. 6. pp. 713-721.
@article{4583d72636da4cba9143e70339ce95d2,
title = "Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic",
abstract = "Background. The safety of adding initial low-dose gentamicin to antistaphylococcal penicillins or vancomycin for treatment of suspected Staphylococcus aureus native valve endocarditis is unknown. This study evaluated the association between this practice and nephrotoxicity. Methods. We performed a prospective cohort study of safety data from a randomized, controlled trial of therapy for S. aureus bacteremia and native valve infective endocarditis involving 236 patients from 44 hospitals in 4 countries. Patients either received standard therapy( antistaphylococcal penicillin or vancomycin) plus initial low-dose gentamicin( n = 116) or received daptomycin monotherapy( n = 120). We measured renal adverse events and clinically significant decreased creatinine clearance in patients( 1) in the original randomized study arms and( 2) who received any initial low-dose gentamicin either, as a study medication or ≥S2 days before enrollment. Results. Renal adverse events occurred in 8( 7{\%}) of 120 daptomycin recipients, 10( 19{\%}) of 53 vancomycin recipients, and 11( 17{\%}) of 63 antistaphylococcal penicillin recipients. Decreased creatinine clearance occurred in 9( 8{\%}) of 113 of evaluable daptomycin recipients, 10( 22{\%}) of 46 vancomycin recipients, and 16( 25{\%}) of 63 antistaphylococcal penicillin recipients. An additional 21 patients received initial low-dose gentamicin >S2 days before study enrollment. A total of 22{\%} of patients who received initial low-dose gentamicin versus 8{\%} of patients who did not receive initial low-dose gentamicin experienced decreased creatinine clearance( P =.005). Independent predictors of a clinically significant decrease in creatinine clearance were age 5≥65 years and receipt of any initial low-dose gentamicin. Conclusions. Initial low-dose gentamicin as part of therapy for S. aureus bacteremia and native valve infective endocarditis is nephrotoxic and should not be used routinely, given the minimal existing data supporting its benefit.",
author = "Cosgrove, {Sara E.} and Vigliani, {Gloria A.} and Marilyn Campion and Fowler, {Vance G.} and Elias Abrutyn and {Ralph Corey}, G. and Levine, {Donald P.} and Rupp, {Mark Edmund} and Chambers, {Henry F.} and Karchmer, {Adolf W.} and Boucher, {Helen W.}",
year = "2009",
month = "3",
day = "15",
doi = "10.1086/597031",
language = "English (US)",
volume = "48",
pages = "713--721",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Initial low-dose gentamicin for staphylococcusaureus bacteremia and endocarditis is nephrotoxic

AU - Cosgrove, Sara E.

AU - Vigliani, Gloria A.

AU - Campion, Marilyn

AU - Fowler, Vance G.

AU - Abrutyn, Elias

AU - Ralph Corey, G.

AU - Levine, Donald P.

AU - Rupp, Mark Edmund

AU - Chambers, Henry F.

AU - Karchmer, Adolf W.

AU - Boucher, Helen W.

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Background. The safety of adding initial low-dose gentamicin to antistaphylococcal penicillins or vancomycin for treatment of suspected Staphylococcus aureus native valve endocarditis is unknown. This study evaluated the association between this practice and nephrotoxicity. Methods. We performed a prospective cohort study of safety data from a randomized, controlled trial of therapy for S. aureus bacteremia and native valve infective endocarditis involving 236 patients from 44 hospitals in 4 countries. Patients either received standard therapy( antistaphylococcal penicillin or vancomycin) plus initial low-dose gentamicin( n = 116) or received daptomycin monotherapy( n = 120). We measured renal adverse events and clinically significant decreased creatinine clearance in patients( 1) in the original randomized study arms and( 2) who received any initial low-dose gentamicin either, as a study medication or ≥S2 days before enrollment. Results. Renal adverse events occurred in 8( 7%) of 120 daptomycin recipients, 10( 19%) of 53 vancomycin recipients, and 11( 17%) of 63 antistaphylococcal penicillin recipients. Decreased creatinine clearance occurred in 9( 8%) of 113 of evaluable daptomycin recipients, 10( 22%) of 46 vancomycin recipients, and 16( 25%) of 63 antistaphylococcal penicillin recipients. An additional 21 patients received initial low-dose gentamicin >S2 days before study enrollment. A total of 22% of patients who received initial low-dose gentamicin versus 8% of patients who did not receive initial low-dose gentamicin experienced decreased creatinine clearance( P =.005). Independent predictors of a clinically significant decrease in creatinine clearance were age 5≥65 years and receipt of any initial low-dose gentamicin. Conclusions. Initial low-dose gentamicin as part of therapy for S. aureus bacteremia and native valve infective endocarditis is nephrotoxic and should not be used routinely, given the minimal existing data supporting its benefit.

AB - Background. The safety of adding initial low-dose gentamicin to antistaphylococcal penicillins or vancomycin for treatment of suspected Staphylococcus aureus native valve endocarditis is unknown. This study evaluated the association between this practice and nephrotoxicity. Methods. We performed a prospective cohort study of safety data from a randomized, controlled trial of therapy for S. aureus bacteremia and native valve infective endocarditis involving 236 patients from 44 hospitals in 4 countries. Patients either received standard therapy( antistaphylococcal penicillin or vancomycin) plus initial low-dose gentamicin( n = 116) or received daptomycin monotherapy( n = 120). We measured renal adverse events and clinically significant decreased creatinine clearance in patients( 1) in the original randomized study arms and( 2) who received any initial low-dose gentamicin either, as a study medication or ≥S2 days before enrollment. Results. Renal adverse events occurred in 8( 7%) of 120 daptomycin recipients, 10( 19%) of 53 vancomycin recipients, and 11( 17%) of 63 antistaphylococcal penicillin recipients. Decreased creatinine clearance occurred in 9( 8%) of 113 of evaluable daptomycin recipients, 10( 22%) of 46 vancomycin recipients, and 16( 25%) of 63 antistaphylococcal penicillin recipients. An additional 21 patients received initial low-dose gentamicin >S2 days before study enrollment. A total of 22% of patients who received initial low-dose gentamicin versus 8% of patients who did not receive initial low-dose gentamicin experienced decreased creatinine clearance( P =.005). Independent predictors of a clinically significant decrease in creatinine clearance were age 5≥65 years and receipt of any initial low-dose gentamicin. Conclusions. Initial low-dose gentamicin as part of therapy for S. aureus bacteremia and native valve infective endocarditis is nephrotoxic and should not be used routinely, given the minimal existing data supporting its benefit.

UR - http://www.scopus.com/inward/record.url?scp=62449226267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449226267&partnerID=8YFLogxK

U2 - 10.1086/597031

DO - 10.1086/597031

M3 - Article

C2 - 19207079

AN - SCOPUS:62449226267

VL - 48

SP - 713

EP - 721

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -